Buy Nootropil solution for internal use 20% 125ml No. 1 in pharmacies

Piracetam
is a nootropic drug, historically the first (synthesized in 1964[3]) and the main representative of this group of drugs; it remains one of the most important in it[4]. Chemically, it is a derivative of pyrrolidone and is the founder of the family of so-called “racetams” [5].

In the United States, piracetam and other nootropics are not registered as medications because their effectiveness in the treatment of dementia and neurodegenerative diseases has not been proven in controlled studies[6]. In the USA, piracetam does not have FDA approval, but is sold as a dietary supplement[7].

In Russia, piracetam is used to treat many diseases[8], since 1999 it has been approved in Japan for the treatment of cortical myoclonus[9], and since 1992 it has been registered in the European Union as a strictly prescription drug[10].

According to research conducted in the USSR, piracetam improves brain function during oxygen deprivation and improves the formation of neural connections during the learning process[11].

In the resolution of the meeting of the Presidium of the Formulary Committee of the Russian Academy of Medical Sciences on March 16, 2007, piracetam was recognized as “an outdated drug with unproven effectiveness”[12]. As of 2021, it is included in the list of vital and essential medicines in the Russian Federation.

Compound

Piracetam is the active ingredient of the drug.
The tablets contain 800 or 1200 mg of this substance. Additional elements: macrogol 6000, silicon dioxide, croscarmellose sodium, magnesium stearate.

Capsules of 400 mg of active ingredient. Additional substances: macrogol 6000, silicon dioxide, lactose monohydrate, magnesium stearate.

The oral solution contains 200 or 330 mg of active substance per 1 ml. Additional elements of the composition are: sodium saccharinate, pure water, glycerol , sodium acetate, acetic acid, methyl parahydroxybenzoate, flavorings, propyl parahydroxybenzoate.

Nootropil solution IV and IM contains 200 mg of active substance per 1 ml. Auxiliary elements are: sodium acetate trihydrate, water for injection, glacial acetic acid.

Pharmacodynamics and pharmacokinetics

The active ingredient is piracetam. The use of the drug Nootropil enhances the utilization of glucose, enhances the synthesis of phospholipids and RNA, increases the level of ATP in brain tissue, and stimulates glycolytic reactions . The drug has a positive effect on metabolic processes in brain tissue, facilitates the learning process, improves integrative work and brain activity, and improves memory . Nootropil is able to suppress the aggregation of activated platelets, does not have a vasodilatory effect, but at the same time has a positive effect on microcirculation and the speed of propagation of the excitation wave in brain tissue. In case of brain damage due to intoxication, hypoxia, or electric shock, the drug has a pronounced protective effect, reducing the severity of vestibular nystagmus, reduces delta activity and enhances alpha and beta activity on the electroencephalogram . The medication improves cerebral blood flow, increases mental performance, improves conductivity between synapses in neocortical structures, and has a positive effect on interhemispheric connections. The therapeutic effect of treatment develops gradually. The drug does not have psychostimulating and sedative effects.

The drug is quickly absorbed, is not metabolized, and does not bind to blood proteins. It is excreted unchanged by the kidneys.

Description[ | ]

Piracetam is the main representative of the group of nootropic drugs. Currently, a number of its direct analogues and homologues (oxiracetam, etiracetam, etc.) similar to it in action have been synthesized, but piracetam continues to be the main drug of this group.

The mechanism of action of the drug is not clear. Its purported effects are still poorly described, and clinical trials were conducted many years ago, using techniques that are not now considered standard[6].

Presumably, piracetam has a positive effect on metabolic processes and blood circulation in the brain. Stimulates redox processes, enhances glucose utilization, improves regional blood flow in ischemic areas of the brain. The drug increases the energy potential of the body by accelerating ATP turnover, increasing the activity of adenylate cyclase and inhibiting nucleotide phosphatase. Improvement in energy processes under the influence of piracetam leads to increased resistance of brain tissue to hypoxia and toxic influences. There is evidence of an increase in the synthesis of nuclear RNA in the brain under the influence of piracetam. [ source not specified 219 days

]

The turnover of dietary supplements with piracetam and other nootropic drugs in the United States reached $640 million in 2015[7].

Indications for use of Nootropil

Instructions for use of the drug Nootropil recommend prescribing the drug in neurology, narcology and psychiatry.

In neurological practice, the medication is used for pathology of the nervous system, accompanied by disturbances in the emotional-volitional sphere (for example, Alzheimer's disease) and a decrease in intellectual and mental functions. The drug is prescribed after intoxication and traumatic brain damage, for chronic cerebrovascular insufficiency (headaches, severe dizziness, speech disorders, attention, memory), for vascular pathology of brain tissue, for comatose and subcomatose states, during the period of convalescence in order to increase mental and motor activity, with residual effects of cerebral circulatory disorders according to the ischemic variant.

Indications for the use of Nootropil in psychiatry: flaccid apathetic defective conditions (such as psychoorganic syndrome, schizophrenia), asthenodepressive syndrome (with a predominance of ideator inhibition, with senesto-hypochondriacal disorders, asthenic pathology, with adynamia), nephrotic syndrome . Piracetam is prescribed in the complex treatment of depressive conditions that are resistant to the effects of antidepressants, in the treatment of mental pathology that occurs on “organically defective soil.” The drug is recommended for use in cases of intolerance to neuroleptics and antipsychotic medications in order to eliminate mental, neurological and somatovegetative complications. The drug is prescribed for the cortical form of myoclonus.

Nootropil in drug treatment practice is used to relieve alcohol withdrawal syndrome , in acute poisoning with phenamine , barbiturates , morphine, ethanol, in morphine withdrawal syndrome, chronic alcoholism (in combination with intellectual and mnestic disorders, asthenia, persistent mental pathology). The drug can be used as part of combination therapy in the treatment of sickle cell anemia .

In order to eliminate the consequences of perinatal damage to brain structures, to improve the learning process, in case of cerebral palsy , mental retardation, Nootropil can be used in pediatrics.

Efficiency[ | ]

The clinical use of piracetam is not justified by scientific data; there is no reliable evidence of effectiveness for it [6][7][13][14].

Research[ | ]

Some studies have suggested that piracetam may provide some benefit, but overall there is limited evidence of its effectiveness for dementia or non-dementia cognitive impairment. A 2004 Cochrane review based on a pooled analysis of data from 24 studies with 11,959 participants showed that piracetam, when compared with placebo, did not significantly improve the condition of patients with dementia, including vascular and Alzheimer's disease, or improve cognitive impairment, not meeting diagnostic criteria for dementia. The authors of the review conclude that further study of the drug is necessary[6].

In 2008, a working group of the British Academy of Medical Sciences noted that many trials of piracetam for dementia were flawed[15]. Published in the journal CNS Drugs

(English) (Russian) in 2021 it was noted that there is no evidence of the benefit of piracetam in vascular dementia[14].

The randomized multicenter placebo-controlled PASS (Piracetam in Acute Stroke Study) trial showed the lack of effectiveness of piracetam in the treatment of acute ischemic stroke. The observed results of using piracetam are similar to those of placebo. In this study, patients received piracetam at a dose of 12 grams per day, therapy began within the first 12 hours from the onset of stroke. Upon additional analysis, however, it was found that the positive effect of piracetam still manifests itself in a subgroup of patients with earlier (up to 7 hours) initiation of therapy for moderate and severe (Orgogozo score less than 55 out of 100 points) stroke [16]. Another study, PASS II, was conducted with the inclusion of 800 patients and the administration of piracetam in the first 7 hours after the onset of stroke [17]. The results of the study were never published by the sponsor[18].

A 2012 Cochrane review also found that there was no evidence of benefit for piracetam in acute ischemic stroke[19].

Another 2012 Cochrane review found there was insufficient evidence to evaluate the use of piracetam for fetal distress during labor[20], and a 2021 Cochrane review found insufficient evidence to evaluate the effectiveness of piracetam when used to prevent painful crises in sickle cell disease[13]. .

Contraindications

The medication is not used for hemorrhagic stroke , with severe pathology of the renal system, or with intolerance to the main substance piracetam. During pregnancy, severe bleeding , after extensive surgical interventions, with pathology of hemostasis and during breastfeeding, Nootropil is prescribed with caution, assessing the possible risks.

Side effects[ | ]

Main source: [1]

• From the nervous system and sensory organs: hyperkinesia (>1%), increased irritability (>1%), drowsiness (<1%), depression (<1%), asthenia (<1%), agitation, aggressive behavior, disorder sleep, dizziness, headache, increased libido, tremor.
• Exacerbation of coronary insufficiency;
• nausea, vomiting, diarrhea, abdominal pain;
• weight gain (>1%);
• skin hypersensitivity reactions.

Side effects

There are the following side effects during treatment: vomiting, nausea, disturbances in concentration, imbalance, motor disinhibition, mental agitation, gastralgia , sleep disturbances, anxiety, appetite disturbances, stool disturbances, increased sexual activity, convulsive syndrome , extrapyramidal disorders, headache, dizziness, tremors of extremities. When angina is diagnosed, the course of the disease worsens. Most often, side effects are recorded when the recommended dose of 5 g per day is exceeded.

Contraindications and side effects

The product has few contraindications. Taking Nootropil is completely excluded only in the presence of hemorrhagic stroke and severe kidney pathologies or acute failure. Another indicator of absolute contraindications is individual intolerance to piracetam or other substances included in the tablets, capsules or solution.

Pregnant and lactating women (at any stage) should use Nootropil with caution. Also, careful use is carried out in the presence of chronic diseases, acute conditions that disrupt homeostasis.

In some cases (especially often when the daily norm exceeds 5 g), taking Nootropil gives a number of side effects:

• nausea;
• vomit;
• deterioration in concentration;
• mood swings;
• retardation of movements;
• mental overexcitation;
• sleep problems;
• high level of anxiety;
• appetite disorders;
• gastralgia;
• increased sexual desire;
• headaches;
• tremor;
• dizziness.

Attention!

Taking the medicine may make your angina worse. Patients suffering from this disease should take the drug only under the supervision of a doctor and in accordance with the dosage.

Instructions for use of Nootropil (Method and dosage)

The drug is prescribed intravenously, intramuscularly and orally.

Instructions for the solution

The initial dosage of the drug for parenteral intravenous administration is 10 g. In severe pathology, the medication is administered intravenously by drip up to 12 g per day, the duration of the infusion is 20-30 minutes. Once the therapeutic effect is achieved, the amount of the drug is reduced with a gradual transition to oral administration.

Nootropil tablets, instructions for use

The drug is taken twice a day, the daily dosage is 30-160 mg per 1 kg. It is possible to increase the frequency of administration to 3-4 times a day if necessary. The course of treatment under this regimen is up to 2-6 months.

When treating memory disorders and cognitive disorders, the medication is prescribed orally at the initial stages of therapy, 1600 mg three times a day, then the amount of the drug is reduced to 800 mg.

Treatment of cerebrovascular diseases in the acute stage should begin as soon as possible with a dose of 12 g per day for two weeks, then switch to a dosage of 6 g per day.

Therapy for cortical myoclonus begins with 7.2 g per day with a gradual increase in the amount of active substance by 4.8 g per day every 3-4 days. The maximum dose is 24 grams in 24 hours.

The daily dosage for sickle cell anemia is 160 mg per 1 kg (4 doses). During a crisis period, the dose is increased to 300 mg per 1 kg.

In case of renal dysfunction, the drug is used with caution. The dose is prescribed by the doctor.

How to take a drug to improve memory?

You need to take the medicine 2 times a day. The following dosage is recommended to improve memory - 8 ml of a 20% solution for oral administration.

Nootropil 800 mg No. 30 tablet p.o.

INSTRUCTIONS FOR MEDICAL USE OF THE MEDICINE NOOTROPIL® TRADE NAME NOOTROPIL® INTERNATIONAL NON-PROPENTED NAME PIracetam DOSAGE FORM FILM-COATED TABLETS, 800 MG COMPOSITION ONE TABLE ITK CONTAINS THE ACTIVE SUBSTANCE – PIRACETAM 800 MG, AUXILIARY SUBSTANCES: SILICON DIOXIDE COLLOIDAL ANHYDROUS, MAGNESIUM STEARATE, POLYETHYLENE GLYCOL 6000, CROSCARMELLOSE SODIUM, COVER COMPOSITION: OPADRAY Y-1-7000 (HYDROXYPROPYL METHYL CELLULOSE, TITANIUM DIOXIDE (E171), POLYETHYLENE GLYCOL 400), OPADRAY OY-S-29019 (HYDROXYPROPYL METHYL CELLULOSE, POLYETHYLENE GLYCOL 6000). DESCRIPTION FILM-COATED TABLETS, WHITE, LONG, WITH SCORES ON BOTH SIDES AND ENGRAVED N ON BOTH SIDES OF SCORES ON ONE SIDE. PHARMACOTHERAPEUTIC GROUP OTHER PSYCHOSTIMULANTS AND NOOTROPIC DRUGS ATC CODE N06BX03 PHARMACOLOGICAL PROPERTIES PHARMACOKINETICS AFTER ORAL USE PIRACETAM IS QUICKLY AND ALMOST COMPLETELY ABSORBED, PEAK CONCENTRATION I AM REACHED 1 HOUR AFTER USE. BIOAVAILABILITY OF THE DRUG IS APPROXIMATELY 100%. AFTER TAKING A SINGLE DOSE OF 2 G, THE MAXIMUM CONCENTRATION IS 40-60 mcg/ml, WHICH IS REACHED IN THE BLOOD AFTER 30 MINUTES. THE APPEARING VOLUME OF DISTRIBUTION OF PIRACETAM IS ABOUT 0.6 L/KG. THE HALF-LIFE OF THE DRUG FROM BLOOD PLASMA IS 4-5 HOURS AND 8.5 HOURS FROM CORESPINAL FLUID, WHICH IS ELONGED IN RENAL FAILURE. THE PHARMACOKINETICS OF PIracetam DOES NOT CHANGE IN PATIENTS WITH LIVER FAILURE. PENETRATES THE BLOOD-BRAIN AND PLACENTAL BARRIER AND MEMBRANES USED IN HEMODIALYSIS. PIRACETAM SELECTIVELY ACCUMULATES IN THE TISSUE OF THE CEREBRAL CORTEX, MAINLY IN THE FRONTAL, PARIETAL AND OCCIPITAL LOBE, IN THE CEREBELLUM AND BASAL GANGLIA. DOES NOT BIND TO BLOOD PLASMA PROTEINS, IS NOT METABOLIZED IN THE BODY AND IS EXCRETED BY THE KIDNEYS IN AN UNCHANGED FORM. 80-100% OF PIRACETAM IS EXCRETED BY THE KIDNEYS IN AN UNMODIFIED FORM BY RENAL FILTRATION. PHARMACODYNAMICS THE ACTIVE COMPONENT OF NOOTROPIL® IS PIRACETAM, A CYCLIC DERIVATIVE OF GAMMA-AMINO-BUTYRY ACID (GABA). NOOTROPIL IS A NOOTROPIL DRUG THAT DIRECTLY AFFECTS THE BRAIN, IMPROVING COGNITIVE (COGNITIVE) PROCESSES SUCH AS LEARNING ABILITY, MEMORY, ATTENTION, AND ALSO MENTAL PERFORMANCE. NOOTROPIL® INFLUENCES THE CENTRAL NERVOUS SYSTEM IN VARIOUS WAYS: BY CHANGING THE RATE OF EXCITATION IN THE BRAIN, IMPROVING METABOLIC PROCESSES IN NERVE CELLS, IMPROVING MICROCIRCULATION, IMPACTS INFLUENCES THE RHEOLOGICAL PROPERTIES OF BLOOD AND DOES NOT CAUSE A VASUDOLATORAL EFFECT. IMPROVES SYNAPTIC CONDUCTION IN NEOCORTICAL STRUCTURES, INCREASES MENTAL PERFORMANCE, IMPROVES CEREBRAL BLOOD FLOW. NOOTROPIL INHIBITS PLATELET AGGREGATION AND RESTORES THE ELASTICITY OF THE erythrocyte membrane, and reduces the adhesion of erythrocytes. WHEN TAKEN AT A DOSE OF 9.6 G, THERE IS A 30% - 40% DECREASE IN FIBRINOGEN AND VILLIBRAND FACTORS AND AN ELONGATION IN BLEEDING TIME. NOOTROPIL HAS A PROTECTIVE AND RESTORATIVE EFFECT WHEN BRAIN FUNCTION IS DISRUPTED DUE TO HYPOXIA AND INTOXICATION. NOOTROPIL REDUCES THE SEVERITY AND DURATION OF VESTIBULAR NYSTAGM. INDICATIONS FOR USE - PSYCHOORGANIC DISORDERS, IN PARTICULAR IN ELDERLY PATIENTS, MANIFESTED BY REDUCED MEMORY, Dizziness, REDUCED CONCENTRATION OF ATTENTION AND REDUCED GENERAL ACTIVITY, MOOD CHANGES, BEHAVIORAL DISORDERS, GAIT DISORDERS AND IN PATIENTS WITH ALZHEIMER'S DISEASE AND SENILIA DEMENTIA OF ALZHEIMER'S TYPE - Dizziness AND ASSOCIATED EQUILIBILITY DISORDERS, EXCEPT FOR DIZZINESS OF VASCULAR AND MENTAL ORIGIN - CORTICAL MYOCLONIUS AS A MONO- OR COMPLEX THERAPY - SICKLE CELL ANEMIA AS A COMPLEX THERAPY - TREATMENT D ISLEXIA IN CHILDREN (IN COMPLEX WITH OTHER METHODS). METHOD OF APPLICATION AND DOSES NOOTROPIL® IS TAKEN ORALLY DURING MEALS OR ON AN EAST SCHATCH WITH LIQUIDS. ATTENTION! TAKE THE LAST SINGLE DOSE NO LATER THAN 5:00 PM TO PREVENT SLEEP DISTURBANCE. THE DAILY DOSE IS RECOMMENDED TO BE TAKEN IN 2-4 SIZES. SYMPTOMATIC TREATMENT OF PSYCHOORGANIC SYNDROME: 4.8 G/DAY DURING THE FIRST WEEK AND THEN GO TO A MAINTENANCE DOSE OF 1.2-2.4 G/DAY TREATMENT OF VERTIGO AND ASSOCIATED EQUILIBRIUM: 2.4 — 4.8 G/ DAILY TREATMENT OF CORTICAL MYOCLONIUS: START WITH A DOSE OF 7.2 G/DAY, EVERY 3-4 DAYS THE DOSE IS INCREASED BY 4.8 G/DAY UNTIL A MAXIMUM DOSE OF 24 G/DAY IS REACHED. TREATMENT CONTINUES DURING THE WHOLE PERIOD OF THE DISEASE. EVERY 6 MONTHS AN ATTEMPT SHOULD BE MADE TO REDUCE THE DOSE OR WITHDRAWAL THE DRUG BY GRADUALLY REDUCING THE DOSE BY 1.2 G/DAY EVERY 2 DAYS. IF THERE IS NO EFFECT OR AN INsignificant THERAPEUTIC EFFECT, THE TREATMENT IS DISCONTINUED. TREATMENT OF SICKLE CELL ANEMIA: THE DAILY PREVENTIVE DOSE IS 160 MG/KG OF BODY WEIGHT, DIVIDED INTO 4 EQUAL DOSES. A DOSE LESS THAN 160 MG/KG OR IRREGULAR TAKING OF THE DRUG MAY CAUSE AN EXacERBATION OF THE DISEASE. TREATMENT OF DYSLEXIA IN CHILDREN (IN COLLECTION WITH OTHER TREATMENT METHODS): RECOMMENDED DAILY DOSE FOR CHILDREN FROM 8 YEARS OLD AND ADOLESCENTS – 3.2 G, DIVIDED INTO 2 ADMISSIONS. SINCE NOOTROPIL® IS EXCLUDED FROM THE BODY BY THE KIDNEYS, WHEN PRESCRIBING THE DRUG TO PATIENTS WITH RENAL FAILURE AND ELDERLY PATIENTS, THE DOSE SHOULD BE ADJUSTED DEPENDING ON THE VALUATION OF CREATININE CLEARANCE (CR). BC FOR MEN CAN BE CALCULATED BASED ON SERUM CREATININE CONCENTRATION USING THE FOLLOWING FORMULA: [140 – AGE (YEARS)] ´ BODY WEIGHT (KG) BC (ML/MIN) = ————————————— ————- 72 X CVS (MG/DL) CV FOR WOMEN CAN BE CALCULATED BY MULTIPLYING THE OBTAINED VALUE BY A COEFFICIENT OF 0.85. NO DOSE CORRECTION IS REQUIRED FOR PATIENTS WITH LIVER FUNCTION IMPAIRMENTS. FOR PATIENTS WITH IMPAIRED RENAL AND LIVER FUNCTIONS, DOSING IS CARRIED OUT ACCORDING TO THE TABLE BELOW. RENAL FAILURE KK (ML/MIN) DOSING REGIMEN NORMAL > 80 USUAL DOSE LIGHT 50-79 2/3 USUAL DOSE IN 2-3 DEPARTMENTS MEDIUM 30-49 1/3 USUAL DOSE IN 2 DETAILS SEVERE <30 1/6 USUAL DOSE ONE MULTIPLE TERMINAL STAGE < 20 CONTRAINDICATED SIDE EFFECTS - HYPERKINESIA, NERVOUSITY, Drowsiness, DEPRESSION, ASTHENIA, - Dizziness, HEADACHES - ATAXIA, IMPAIRED EQUILIBRIUM, ACHIEVEMENT OF EPILEPSY, ANXIETY, HALLUCINATIONS - DER MATITIS, ITCHING, SKIN RASHE, SWELLING - NAUSEA, VOMITING, DIARRHEA, ABDOMINAL PAIN. CONTRAINDICATIONS - INCREASED SENSITIVITY TO PIRACETAM OR PYRROLIDONE DERIVATIVES, AS WELL AS OTHER COMPONENTS OF THE DRUG - PSYCHOMOTOR EXCITATION AT THE TIME OF PRESCRIPTION OF THE DRUG - HUNTINGTON'S CHOREA - ACUTE CEREBRAL CIRCULATION (HEMORRHA) GYCAL STROKE) - TERMINAL STAGE RENAL FAILURE (CC < 15 ML/MIN) - CHILDHOOD UP TO 6 YEARS - PREGNANCY AND LACTATION WITH CAUTION: - IMPAIRED HEMOSTASIS - EXTENSIVE SURGICAL INTERVENTIONS - SEVERE BLEEDING Drug interactions Nootropil increases the effectiveness of thyroid hormones and antipsychotic drugs (neuroleptics). When administered simultaneously with antipsychotics, nootropil reduces the risk of extrapyramidal disorders. When used simultaneously with drugs that stimulate the central nervous system, their effect on the central nervous system may be enhanced. There was no interaction with clonazepam, phenytoin, phenobarbital, or sodium valproate. Nootropil in high doses (9.6 g/day) increases the effectiveness of indirect anticoagulants in patients with venous thrombosis (a more pronounced decrease in platelet aggregation, fibrinogen levels, von Willebrand factors, blood and plasma viscosity was observed compared with the use of indirect anticoagulants only). The possibility of changing the pharmacodynamics of nootropil under the influence of other drugs is low, because 90% of the drug is excreted unchanged in the urine. Nootropil does not inhibit cytochrome P450 isoenzymes. Metabolic interaction with other drugs is unlikely. When taking nootropil at a dose of 20 mg/day, Cmax in the blood plasma and the nature of the pharmacokinetic curve of antiepileptic drugs (carbamazepine, phenytoin, phenobarbital, valproate) in patients with epilepsy receiving constant doses of these drugs do not change. When piracetam 1.6 g was taken together with alcohol, the serum concentrations of piracetam and ethanol did not change. Special instructions When treating cortical myoclonus, abrupt interruption of treatment should be avoided, as this may cause resumption of attacks. When treating sickle cell anemia, a dose of less than 160 mg/kg or irregular use of the drug may cause an exacerbation of the disease. When treating patients on a hyposodium diet, it is recommended to take into account that piracetam tablets at a dose of 24 g contain 46 mg of sodium. Penetrates through the filter membranes of hemodialysis machines. Features of the effect of the drug on the ability to drive a vehicle or potentially dangerous mechanisms Taking into account possible side effects, care should be taken when driving a car and working with mechanisms. Overdose Symptoms: dyspeptic symptoms such as bloody diarrhea and abdominal pain. Treatment: immediately after taking the drug orally, you can rinse the stomach or induce artificial vomiting. Symptomatic therapy is recommended, which may include hemodialysis. There is no specific antidote. The effectiveness of hemodialysis for piracetam is 50-60%. Release form and packaging: 15 tablets in PVC/aluminum foil strip packaging. 2 contour packages together with instructions for medical use in the state and Russian languages ​​are placed in a cardboard box. Storage conditions: In a dry place at a temperature not exceeding +25°C. Keep out of the reach of children! Shelf life 4 years Do not use after the expiration date indicated on the package! Conditions for dispensing from pharmacies By prescription Manufacturer: USB Pharma S.A. Cheman du Foret B-1420 Brain-l'Alley, Belgium Address of the organization that accepts claims from consumers regarding the quality of products (products) in the Republic of Kazakhstan Representative office in the Republic of Kazakhstan, 050000, Almaty, st. Tolebi 69, office 21 tel.: +, fax

special instructions

Treatment with Nootropil requires regular monitoring of the functioning of the renal and hepatic systems, the state of peripheral blood , the level of creatinine and residual nitrogen. Drug therapy can be combined with psychoactive drugs and medications for the treatment of cardiovascular diseases. Treatment of acute lesions of tissues and structures of the brain is recommended to be carried out in combination with methods of restorative medicine and detoxification therapy . For psychiatric diseases, psychoactive drugs are simultaneously prescribed. Abrupt discontinuation of the medication is unacceptable, especially when treating patients suffering from cortical myoclonus ( due to the high risk of recurrence of seizures and seizures). If side effects such as insomnia or excessive drowsiness develop, it is recommended to stop taking the medication in the evening. During hemodialysis, Nootropil penetrates through special filter membranes in the device. Piracetam affects the ability to drive a vehicle.

The drug is not described in Wikipedia.

Contraindications[ | ]

Hypersensitivity to piracetam and pyrrolidone derivatives; hemorrhagic stroke, severe renal failure (creatinine clearance less than 20 ml/min), agitated depression, Huntington's disease, pregnancy, breastfeeding, children under 1 year of age [1].

Restrictions on use[ | ]

Impaired hemostasis, severe bleeding, during major surgical operations; hyperthyroidism; epilepsy.

People with severe cerebral atherosclerosis should not take the drug, since an increase in metabolism in the nervous tissue under the influence of the drug can lead to increased symptoms of dementia and irreversible deterioration of cognitive functions. This condition occurs due to the inability of the brain vessels to provide a sufficient flow of metabolites.

Persons prone to neurotic reactions should take into account that the drug, with long-term use, causes an increase in the level of anxiety, which can lead to sleep disturbances (mainly insomnia) and an indirect decrease in intellectual functions due to deterioration in concentration.

Use during pregnancy and breastfeeding: contraindicated during pregnancy; breastfeeding should be stopped during treatment.

Analogues of Nootropil

Level 4 ATX code matches:
Bravinton

Acefen

Carnicetine

Pyracesin

Nooclerin

Semax

Piracetam

Olatropil

Fezam

Vinpocetine

Cerebrocurin

Cavinton Forte

Calcium hopantenate

Glutamic acid

Cephabol

Olanzapine

Cerebrolysate

Pramistar

Sidnocarb

Vinpotropil

Analogues are the following drugs: Biotropil , Lucetam , Piracetam .

The price of Nootropil analogues is lower and higher. For example, Piracetam costs less.

Which is better: Nootropil or Piracetam?

The medicines are generics, that is, they contain one active substance, piracetam, and have a similar effect on the body. The drug Piracetam is domestically produced and therefore costs less, however, it is also considered less purified.

Reviews about Nootropil

According to reviews of Nootropil on the forums, memory pills are very useful. They improve brain activity, help memorize large amounts of information, add energy and invigorate.

The drug also helps for its intended purpose, but does not act immediately. Based on reviews for children who used this medication, Nootropil is also useful for delayed speech development in a child.

The disadvantages include a bitter taste, individual intolerance to the drug, as well as side effects, for example, headaches.

Nootropil price, where to buy

The price of Nootropil tablets is 275 rubles for 30 pieces of 800 mg each. You can buy Nootropil in the same release form in Ukraine for 80-100 hryvnia.

The price of Nootropil 20% solution ampoules of 5 ml is 315 rubles for 12 pieces. In Ukraine - 170 hryvnia.

• Online pharmacies in RussiaRussia
• Online pharmacies in UkraineUkraine
• Online pharmacies in KazakhstanKazakhstan

LuxPharma* special offer

• Nootropil tab.
  800 mg No. 30 RUB 1,390 order
• Nootropil tab. 1200 mg No. 20

  RUB 1,460 order

show more

Pharmacy24

• Nootropil 1200 mg No. 20 tablets USB Pharma S.A., Belgium
  119 UAH order
• Nootropil 200 mg/ml 5 ml No. 12 solution Eisika Pharmaceuticals S.R.L., Italy

  168 UAH order

• Nootropil 800 mg No. 30 tablets USB Pharma S.A., Belgium

  95 UAH order

PaniPharmacy

• Nootropil ampoule Nootropil solution 20% amp. 5ml No. 12 Italy, Aesica Pharmaceuticals

  180 UAH order

• Nootropil tablet. p/o 1200 mg No. 20 Ukraine, UCB Pharma

  143 UAH order

• Nootropil tablets Nootropil tablets. p/o 800 mg No. 30 Belgium, UCB Pharma

  112 UAH order

show more

Notes[ | ]

1. ↑ 1 2 3
   Piracetam
   (undefined)
   .
   Encyclopedia of Medicines
   . Register of Medicines of Russia (2002). Access date: October 27, 2011.
2. Search in the drug database, search options: INN - Piracetam
   , flags
   “Search in the register of registered drugs”
   ,
   “Search TKFS”
   ,
   “Show lekforms” (undefined)
   (inaccessible link).
   Circulation of medicines
   . Federal State Institution “Scientific Center for Expertise of Medical Products” of Roszdravnadzor of the Russian Federation (March 27, 2008). — A standard clinical and pharmacological article is a by-law and is not protected by copyright in accordance with part four of the Civil Code of the Russian Federation No. 230-FZ of December 18, 2006. Access date: May 3, 2008. Archived September 3, 2011.
3. Dr. Corneliu E. Giurgea – The Father of Nootropics
4. ↑ 12
   Mashkovsky, 2005, pp. 111-113.
5. S. Shorvon. Pyrrolidone derivatives // The Lancet, 2001, V. 358, P. 1885-1892.
6. ↑ 1 2 3 4 Flicker, L.
   Piracetam for dementia or cognitive impairment: [English] / L. Flicker, EJ Grimley // Cochrane Database of Systematic Reviews. - 2001. - No. 2. - Art. No. CD001011. - doi:10.1002/14651858.CD001011.
7. ↑ 1 2 3 Cohen, PA
   Presence of Piracetam in Cognitive Enhancement Dietary Supplements: [English] / PA Cohen, I. Zakharevich, R. Gerona // JAMA Internal Medicine: journal. — 2021. — Vol. 180, no. 3. - P. 458–459. - doi:10.1001/jamainternmed.2019.5507. - PMID 31764936. - PMC 6902196.
8. Vostrikov, V.V.
   The place of piracetam in modern practical medicine // Reviews on clinical pharmacology and drug therapy: journal. — 2021. — No. 1. — pp. 14–25. — UDC 615.21(G). - doi:10.17816/RCF15114-25.
9. |title=UCB's piracetam approved in Japan |edition=The Pharma Letter |year=1999 |month=11 |day=25 |link=https://www.thepharmaletter.com/article/ucb-s-piracetam-approved-in -japan }}
10. Nootropil Tablets 800 mg: [arch. May 1, 2021] / UCB Pharma Limited // EMC. — 2021. — September 2.
11. Karkishchenko, Nikolai Nikolaevich. Psychounitropism of drugs - M.: Medicine, 1993. ISBN 5-225-02213-8
12. RESOLUTION of the Meeting of the Presidium of the Formal Committee of the Russian Academy of Medical Sciences on March 16, 2007, RAMS
13. ↑ 1 2 Al Hajeri, A.
    Piracetam for reducing the incidence of painful sickle cell disease crises. : [English] / A. Al Hajeri, Z. Fedorowicz // The Cochrane Database Of Systematic Reviews. — 2021. — Vol. 2. - Art. noCD006111. - doi:10.1002/14651858.CD006111.pub3. — PMID 26869149. []
14. ↑ 1 2 Farooq MU, Min J., Goshgarian C., Gorelick PB
    Pharmacotherapy for Vascular Cognitive Impairment. (English) // CNS Drugs. — 2021. — September (vol. 31, no. 9). — P. 759—776. - doi:10.1007/s40263-017-0459-3. — PMID 28786085. []
15. Brain science, addiction and drugs : [English] : [arch. April 20, 2021] : report / An Academy of Medical Sciences working group report chaired by Professor Sir Gabriel Horn FRS FRCP. - Academy of Medical Sciences, 2008. - May. — P. 145. — 216 ​​p. — ISBN 978-1-903401-18-7. — ISBN 1-903401-18-6.
16. Peter Paul De Deyn, Jacques De Reuck, Walter Deberdt, Robert Vlietinck, Jean-Marc Orgogozo.
    Treatment of Acute Ischemic Stroke With Piracetam (English) // Stroke (English) (Russian. - Lippincott Williams & Wilkins (English) (Russian, 1997. - Vol. 28, no. 12. - P. 2347 -2352. - ISSN 0039-2499. - doi:10.1161/01.STR.28.12.2347.
17. Major Ongoing Stroke Trials. (English) // Stroke (English) (Russian. - Lippincott Williams & Wilkins (English) (Russian, 2000. - Vol. 31, no. 6. - P. 1474-1480. - ISSN 0039- 2499. - doi:10.1161/01.STR.31.6.1474.
18. Graeme J. Hankey, Stefano Ricci, Maria Grazia Celani, Teresa Anna Cantisani, Enrico Righetti.
    Piracetam for Acute Ischemic Stroke (English) // Stroke (English) (Russian.. - Lippincott Williams & Wilkins (English) (Russian, 2006. - Vol. 37, no. 8. - P. 2191-2192 - ISSN 0039-2499 - doi:10.1161/01.STR.0000231643.42650.a9.
19. Ricci, S.
    Piracetam for acute ischemic stroke: [English] / S. Ricci, MG Celani, TA Cantisani ... // The Cochrane Database Of Systematic Reviews. - 2012. - No. 9. - Art.no CD000419. - doi:10.1002/14651858.CD000419.pub3. — PMID 22972044. []
20. Hofmeyr, GJ
    Piracetam for fetal distress in labor: [English] / GJ Hofmeyr, R. Kulier // The Cochrane Database Of Systematic Reviews. - 2012. - No. 6. - Art. no CD001064. - doi:10.1002/14651858.CD001064.pub2. — PMID 22696322. []
21. Veselyekiy I. Sh., Voronyuk M. I.
    The effect of piracetam on central hemodynamics in patients with atherosclerosis with discircular encephalopathy. // Wedge. Med. - 1986. - No. 6. - P. 41-44
22. Sharava E.V., Potapov A.A., Kulikov M.A.
    The effect of piracetam on the functional activity of the brain in patients with traumatic brain injury. // Journal. neuropathol. and a psychiatrist. - 1988 - No. 5. - P. 42-48
23. Eninya G.I.
    Timofeeva T. N. Piracetam and indicators of cerebral hemodynamics, lipid metabolism and rheological properties of blood in initial forms of cerebrovascular accident. // Journal. neuropathol. and a psychiatrist. - 1990. - No. 11 - P. 20-23.
24. Pimenov L. T., Kalinina S. A., Churshin A. D.
    Clinical and hemodynamic effectiveness of piracetam (nootropil) in patients with coronary heart disease in the elderly and senile at the outpatient stage of rehabilitation. // Cardiol. - 1992. - No. 5. - P. 35-38
25. Pimenov L. T., Churshin A. D., Ezhov A. V.
    On the ability of piracetam and tocopherol acetate to potentiate the clinical effectiveness of antianginal drugs in patients with coronary heart disease. // Wedge. honey. - 1997. - No. 1. - P. 32-35.
26. Niss A.I., Umansky K.G. et al.
    On the effectiveness of treatment of acute viral neuroinfections with piracetam. // Journal. neuropathol. and a psychiatrist. - 1985. - No. 2. - P. 189-195.
27. Entin G. M.
    Treatment of alcoholism. - M.: Medicine, 1990.
28. Mashkovsky M. D., Andreeva N. I., Parshin V. A.
    The effect of piracetam on the effect of antidepressants. // Journal. neuropathol. and a psychiatrist. - 1989. - No. 2. - P. 129-131.
29. Leshchinsky L. A., Pimenov L. T., Fedorov V. S.
    Therapeutic use of piracetam in patients with myocardial infarction. // Cardiol. - 1987. - No. 2 - P. 46-49.
30. Malykh AG, Sadaie MR
    Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders (English) // Drugs (English) (Russian. - Adis International, February 2010. - No. 70 (3 ) - P. 287-312.
31. A.H. Gouliaev, A. Senning.
    Piracetam and other structurally related nootropics // Brain Research. Brain Research Reviews. - May 1994. - No. 19(2). — P. 180—222.